172 related articles for article (PubMed ID: 32175324)
1. Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout.
Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM
Front Med (Lausanne); 2020; 7():63. PubMed ID: 32175324
[TBL] [Abstract][Full Text] [Related]
2. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM
PLoS One; 2020; 15(6):e0234909. PubMed ID: 32574194
[TBL] [Abstract][Full Text] [Related]
3. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
[No Abstract] [Full Text] [Related]
4. Urate-lowering therapy exerts protective effects against hypertension development in patients with gout.
Lin KH; Yen FS; Li HL; Wei JC; Hsu CC; Yang CC; Hwu CM
J Hum Hypertens; 2021 Apr; 35(4):351-359. PubMed ID: 32366929
[TBL] [Abstract][Full Text] [Related]
5. Urate-lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink.
Kiddle SJ; Sundell KA; Perl S; Nolan S; Bjursell M
Clin Cardiol; 2024 Jun; 47(6):e24297. PubMed ID: 38873862
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights From a Population-Based, Propensity Score-Matched Analysis.
Tai CJ; Wu CC; Lee KT; Tseng TG; Wang HC; Chang FR; Yang YH
Clin Pharmacol Ther; 2022 Mar; 111(3):655-663. PubMed ID: 34719019
[TBL] [Abstract][Full Text] [Related]
7. Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.
Russell MD; Roddy E; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
Rheumatology (Oxford); 2023 Jul; 62(7):2426-2434. PubMed ID: 36355461
[TBL] [Abstract][Full Text] [Related]
8. Effect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout: A Case-Matched Cohort Study.
Chen JH; Lan JL; Cheng CF; Liang WM; Lin HY; Tsay GJ; Yeh WT; Pan WH
PLoS One; 2015; 10(12):e0145193. PubMed ID: 26683302
[TBL] [Abstract][Full Text] [Related]
9. Effect of Urate-lowering Therapy on the Risk of Cardiovascular Disease and All-cause Mortality in Patients with Gout: A Case-matched Cohort Study.
Chen JH; Lan JL; Cheng CF; Liang WM; Lin HY; Tsay GJ; Yeh WT; Pan WH
J Rheumatol; 2015 Sep; 42(9):1694-701. PubMed ID: 26077411
[TBL] [Abstract][Full Text] [Related]
10. Atrial Fibrillation Risk and Urate-Lowering Therapy in Patients with Gout: A Cohort Study Using a Clinical Database.
Liu CH; Huang SC; Yin CH; Huang WC; Chen JS; Chen YS; Gan ST; Tzou SJ; Hsu CT; Wu HM; Wang WH
Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672567
[TBL] [Abstract][Full Text] [Related]
11. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
Chang HW; Lin YW; Lin MH; Lan YC; Wang RY
PLoS One; 2019; 14(1):e0210085. PubMed ID: 30615649
[TBL] [Abstract][Full Text] [Related]
12. Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study.
Fang YJ; Chung YL; Lin CL; Lim YP
Biomed Res Int; 2020; 2020():6358954. PubMed ID: 32775432
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with initiation and persistence of urate-lowering therapy.
Dehlin M; Ekström EH; Petzold M; Strömberg U; Telg G; Jacobsson LT
Arthritis Res Ther; 2017 Jan; 19(1):6. PubMed ID: 28095891
[TBL] [Abstract][Full Text] [Related]
14. Management of gout following 2016/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom.
Russell MD; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
Lancet Reg Health Eur; 2022 Jul; 18():100416. PubMed ID: 35814340
[TBL] [Abstract][Full Text] [Related]
15. Urate-lowering therapy is associated with a reduced risk of arrhythmias: a systematic review and meta-analysis.
Waitayangkoon P; Leesutipornchai T; Techasatian W; Aiumtrakul N; Tanariyakul M; Arayangkool C; Kanthajan T; Nagamine T; Kewcharoen J
J Rheum Dis; 2024 Apr; 31(2):108-115. PubMed ID: 38559794
[TBL] [Abstract][Full Text] [Related]
16. Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.
Beslon V; Moreau P; Maruani A; Maisonneuve H; Giraudeau B; Fournier JP
J Gen Intern Med; 2018 Mar; 33(3):358-366. PubMed ID: 29204974
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Zhang T; Pope JE
Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
[TBL] [Abstract][Full Text] [Related]
18. Urate-lowering treatment and risk of total joint replacement in patients with gout.
Kuo CF; Chou IJ; See LC; Chen JS; Yu KH; Luo SF; Hsieh AH; Zhang W; Doherty M
Rheumatology (Oxford); 2018 Dec; 57(12):2129-2139. PubMed ID: 30060176
[TBL] [Abstract][Full Text] [Related]
19. Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on
Fang YJ; Wu TY; Lin CL; Su CY; Li JR; Chung YL; Tien N; Lim YP
Mediators Inflamm; 2020; 2020():8890300. PubMed ID: 33273891
[TBL] [Abstract][Full Text] [Related]
20. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan.
Hakoda M; Kasagi F
Mod Rheumatol; 2019 Sep; 29(5):880-884. PubMed ID: 30175646
[No Abstract] [Full Text] [Related]
[Next] [New Search]
